Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,193,163 papers from all fields of science
Search
Sign In
Create Free Account
pipequaline
Known as:
2-phenyl-4-(2-(4-piperidinyl)ethyl)quinoline
, Quinoline, 2-phenyl-4-(2-(4-piperidinyl)ethyl)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Anticonvulsants
Quinolines
Narrower (1)
PK 8165
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
The effects on memory of pipequaline, alone or in combination with diazepam
F. Eves
,
H. Curran
,
P. Shine
,
M. Lader
Psychopharmacology
2004
Corpus ID: 20460757
Pipequaline (PK 8165) is a putative mixed agonist/antagonist at benzodiazepine receptors. The effects of pipequaline and diazepam…
Expand
1991
1991
Liaisons sanguines, transferts cérébral et hépatique de la pipequaline
Dalila Essassi
1991
Corpus ID: 81892530
Les liaisons proteiques plasmatiques de la pipequaline sont etudiees par dialyse a l'equilibre. In vitro, son pourcentage de…
Expand
1989
1989
Pipequaline Transport from Blood to Brain and Liver: Role of Plasma Protein‐bound Drug
Dalila Essassi
,
S. Urien
,
R. Zini
,
J. Tillement
The Journal of pharmacy and pharmacology
1989
Corpus ID: 35323091
Brain uptake of pipequaline (45319 RP) has been studied in‐vivo after a single capillary transit by intracarotid injection to…
Expand
1987
1987
Binding in vitro of pipequaline (45319 RP) onto plasma proteins and blood cells in man.
D. Essassi
,
R. Zini
,
+4 authors
J. Tillement
Biochemical Pharmacology
1987
Corpus ID: 1653135
1987
1987
Pipequaline acts as a partial agonist of benzodiazepine receptors: An electrophysiological study in the hippocampus of the rat
G. Debonnel
,
C. Montigny
Neuropharmacology
1987
Corpus ID: 38530030
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE